Akebia Therapeutics (AKBA) Capital Expenditures Growth (5y) (2018 - 2026)
Akebia Therapeutics (AKBA) Capital Expenditures Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.72 Bn | 30.78 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.11 Bn | 20.96 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.88 Bn | 16.56 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Akebia Therapeutics | 340.48 Mn | 177.88 Mn | 41.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.59% |
| Dec 31, 2025 | 21.45% |
| Sep 30, 2025 | -58.91% |
| Jun 30, 2025 | 68.18% |
| Mar 31, 2025 | 19.05% |
| Dec 31, 2024 | 43.51% |
| Sep 30, 2024 | -28.19% |
| Jun 30, 2024 | -20.48% |
| Mar 31, 2024 | -20.48% |
| Dec 31, 2023 | -63.96% |
| Sep 30, 2023 | 63.63% |
| Jun 30, 2023 | -66.92% |
| Mar 31, 2023 | 56.87% |
| Sep 30, 2022 | 167.52% |
| Jun 30, 2022 | -77.00% |
| Mar 31, 2022 | -62.38% |
| Sep 30, 2021 | 27.36% |
| Jun 30, 2021 | -33.45% |
| Mar 31, 2021 | -70.68% |
| Dec 31, 2020 | -51.18% |